Literature DB >> 32226245

Therapeutic Targets in Telomerase and Telomere Biology of Cancers.

Rajendra Prasad1, Deeksha Pal2, Wajid Mohammad1.   

Abstract

Telomeres play an important role to conserve genomic integrity by protecting the ends of chromosomes in normal cells. Since, their progressive shortening during successive cell division which lead to chromosomal instability. Notably, telomere length is perpetuated by telomerase in large majority of cancers, thereby ensure indefinite cell proliferation-a hallmark of cancer-and this unique feature has provided telomerase as the preferred target for drug development in cancer therapeutics. Cancer cells have acquired the potential to have telomere length maintenance by telomerase activation- up-regulation of hTERT gene expression in tumor cells is synchronized by multiple genetic and epigenetic modification mechanisms viz hTERT structural variants, hTERT promoter mutation and epigenetic modifications through hTERT promoter methylation which have been implicated in various cancers initiation and progression. In view of these facts, strategies have been made to target the underlining molecular mechanisms involved in telomerase reactivation as well as of telomere structure with special reference to distortion of sheltrin proteins. This review is focussed on extensive understanding of telomere and telomerase biology. which will provide indispensable informations for enhancing the efficiency of rational anticancer drug design. However, there is also an urgent need for better understanding of cell signalling pathways for alternative lengthening of telomere which is present in telomerase negative cancer for therapeutic targets. © Association of Clinical Biochemists of India 2020.

Entities:  

Keywords:  ALT; Anticancer therapy; Epigenetics; Shelterin; Telomerase; Telomere; hTERT promoter mutations

Year:  2020        PMID: 32226245      PMCID: PMC7093628          DOI: 10.1007/s12291-020-00876-8

Source DB:  PubMed          Journal:  Indian J Clin Biochem        ISSN: 0970-1915


  114 in total

1.  Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma.

Authors:  Xiaoli Liu; Guojun Wu; Yuan Shan; Christian Hartmann; Andreas von Deimling; Mingzhao Xing
Journal:  Cell Cycle       Date:  2013-04-19       Impact factor: 4.534

Review 2.  Highlights in experimental therapeutics.

Authors:  Angelika M Burger
Journal:  Cancer Lett       Date:  2006-05-02       Impact factor: 8.679

3.  Highly recurrent TERT promoter mutations in human melanoma.

Authors:  Franklin W Huang; Eran Hodis; Mary Jue Xu; Gregory V Kryukov; Lynda Chin; Levi A Garraway
Journal:  Science       Date:  2013-01-24       Impact factor: 47.728

4.  Epigenetic regulation of telomere length in mammalian cells by the Suv39h1 and Suv39h2 histone methyltransferases.

Authors:  Marta García-Cao; Roderick O'Sullivan; Antoine H F M Peters; Thomas Jenuwein; María A Blasco
Journal:  Nat Genet       Date:  2003-12-14       Impact factor: 38.330

5.  Mutations of the TERT promoter are common in basal cell carcinoma and squamous cell carcinoma.

Authors:  Glynis A Scott; Todd S Laughlin; Paul G Rothberg
Journal:  Mod Pathol       Date:  2013-09-13       Impact factor: 7.842

6.  Telomere uncapping by the G-quadruplex ligand RHPS4 inhibits clonogenic tumour cell growth in vitro and in vivo consistent with a cancer stem cell targeting mechanism.

Authors:  P Phatak; J C Cookson; F Dai; V Smith; R B Gartenhaus; M F G Stevens; A M Burger
Journal:  Br J Cancer       Date:  2007-04-03       Impact factor: 7.640

Review 7.  Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies.

Authors:  Mohammad A Jafri; Shakeel A Ansari; Mohammed H Alqahtani; Jerry W Shay
Journal:  Genome Med       Date:  2016-06-20       Impact factor: 11.117

8.  Reduction in H3K4me patterns due to aberrant expression of methyltransferases and demethylases in renal cell carcinoma: prognostic and therapeutic implications.

Authors:  Aman Kumar; Niti Kumari; Ujjawal Sharma; Sant Ram; Shrawan Kumar Singh; Nandita Kakkar; Karanvir Kaushal; Rajendra Prasad
Journal:  Sci Rep       Date:  2019-06-03       Impact factor: 4.379

9.  siRNA inhibition of telomerase enhances the anti-cancer effect of doxorubicin in breast cancer cells.

Authors:  Xuejun Dong; Anding Liu; Cindy Zer; Jianguo Feng; Zhuan Zhen; Mingfeng Yang; Li Zhong
Journal:  BMC Cancer       Date:  2009-05-05       Impact factor: 4.430

10.  Human telomerase RNA and box H/ACA scaRNAs share a common Cajal body-specific localization signal.

Authors:  Beáta E Jády; Edouard Bertrand; Tamás Kiss
Journal:  J Cell Biol       Date:  2004-02-23       Impact factor: 10.539

View more
  1 in total

Review 1.  Telomeres and Cancer.

Authors:  Hueng-Chuen Fan; Fung-Wei Chang; Jeng-Dau Tsai; Kao-Min Lin; Chuan-Mu Chen; Shinn-Zong Lin; Ching-Ann Liu; Horng-Jyh Harn
Journal:  Life (Basel)       Date:  2021-12-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.